Latest & greatest articles for budesonide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on budesonide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on budesonide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for budesonide

61. Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review

Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

62. Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study

Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

63. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study

Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

64. Combined budesonide and formoterol for maintenance and relief provided better asthma control than budesonide for maintenance and terbutaline for relief

Combined budesonide and formoterol for maintenance and relief provided better asthma control than budesonide for maintenance and terbutaline for relief Combined budesonide and formoterol for maintenance and relief provided better asthma control than budesonide for maintenance and terbutaline for relief | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn (...) more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Combined budesonide and formoterol for maintenance and relief provided better asthma

2006 Evidence-Based Medicine

65. Budesonide for induction of remission in Crohn's disease. (Abstract)

Budesonide for induction of remission in Crohn's disease. Corticosteroids continue to play a central role in induction of remission in active Crohn's disease. However, their use comes at a price of significant adverse effects when used repeatedly or for extended periods. Newer corticosteroid agents with limited systemic bioavailability offer a tantalizing option, if they can be shown to be efficacious and safer than conventional corticosteroids. Budesonide is the main alternative corticosteroid (...) currently available in an enteric formulation.To evaluate the effectiveness of oral budesonide for the treatment of acute flares of Crohn's disease. A secondary but important endpoint was to evaluate the adverse effect profile.The following sources were used to search the literature for potentially relevant papers and trials. 1. A computer-assisted search of the on-line bibliographic database MEDLINE from 1986 onwards. 2. Hand searching the reference lists of trials and review articles identified

2005 Cochrane

66. Budesonide increased symptom free days in patients with recent onset mild asthma at an additional cost of US$0.42/day Full Text available with Trip Pro

% women; based on 7165 patients) who had received a diagnosis of asthma ⩽2 years before randomisation and had mild persistent asthma (ie, ⩾1 symptom such as wheeze, cough, or chest tightness per week, but not as often as every day, during the previous 3 mo) and airway reversibility. Exclusion criteria: significant comorbidity. Interventions: budesonide (Pulmicort Turbuhaler, AstraZeneca, London, UK), 400 μg (200 μg for children <11 y) once daily {n = 3642} or usual care {n = 3599} . As appropriate (...) Budesonide increased symptom free days in patients with recent onset mild asthma at an additional cost of US$0.42/day Budesonide increased symptom free days in patients with recent onset mild asthma at an additional cost of US$0.42/day | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your

2005 Evidence-Based Medicine

67. Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma

Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma Bruggenjurgen B, Selim D, Kardos P, Richter K, Vogelmeier C, Roll S, Meyer-Sabellek W, Buhl (...) R, Willich S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two strategies for the treatment of asthma were examined, adjustable maintenance versus fixed treatment. Both strategies were based on a combination of budesonide

2005 NHS Economic Evaluation Database.

68. Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone Lofdahl C G, Ericsson A, Svensson K, Andreasson E Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the combination of budesonide and formoterol (B/F) in a single inhaler for the treatment of chronic obstructive pulmonary disease (COPD). The patients received two inhalations of B/F (160/4.5 microg) twice daily. Type of intervention Treatment. Economic study type

2005 NHS Economic Evaluation Database.

69. Budesonide once versus twice-daily administration: meta-analysis

Budesonide once versus twice-daily administration: meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 DARE.

70. An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study

An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

71. Country-specific cost-effectiveness early intervention with budesonide in mild asthma

Country-specific cost-effectiveness early intervention with budesonide in mild asthma Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

72. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. (Abstract)

Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Although inhaled glucocorticosteroids are recommended for persistent asthma, their long-term effect on recent onset, mild, persistent asthma has yet to be established.We did a randomised, double-blind clinical trial in 7241 patients in 32 countries to assess the effects of budesonide in patients who had had mild persistent asthma for less than 2 years and who had not had previous regular treatment (...) with glucocorticosteroids. Patients aged 5-66 years received either budesonide or placebo once daily for 3 years in addition to their usual asthma medications. The daily budesonide dose was 400 microg, or 200 microg for children younger than 11 years. The primary outcome was time to first severe asthma-related event, and analysis was by intention to treat.198 of 3568 patients on placebo and 117 of 3597 on budesonide had at least one severe asthma exacerbation; hazard ratio 0.56 (95% CI 0.45-0.71, p<0.0001). Patients

2003 Lancet Controlled trial quality: predicted high

73. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma

Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2003 NHS Economic Evaluation Database.

74. Fluticasone versus beclomethasone or budesonide for chronic asthma. (Abstract)

Fluticasone versus beclomethasone or budesonide for chronic asthma. Beclomethasone dipropionate (BDP) and budesonide (BUD) are commonly prescribed inhaled corticosteroids for the treatment of asthma, Fluticasone propionate (FP) is newer agent with greater potency in in-vitro assays.To compare the efficacy and safety of Fluticasone to Beclomethasone or Budesonide in the treatment of chronic asthma.We searched the Cochrane Airways Group Trial Register (1999) and reference lists of articles. We (...) contacted trialists and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997-1999).Randomised trials in children and adults comparing Fluticasone to either Beclomethasone or Budesonide in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality.One reviewer extracted data. Quantitative analyses where undertaken using Review Manager 4.0.3 with Metaview 3.1.42 studies (>10,000

2002 Cochrane

75. Inhaled beclomethasone versus budesonide for chronic asthma. (Abstract)

Inhaled beclomethasone versus budesonide for chronic asthma. Beclomethasone dipropionate (BDP) and budesonide (BUD) are used widely in the treatment of chronic asthma. The two drugs have different in vitro pharmacokinetic characteristics. It is unclear whether this translates into clinically significant differences in efficacy or safety when treating children and adults with chronic asthma.To assess clinical outcomes in studies which have compared inhaled BDP and BUD in the treatment of chronic

2002 Cochrane

76. Systematic review: the effectiveness of budesonide therapy for Crohn's disease

Systematic review: the effectiveness of budesonide therapy for Crohn's disease Systematic review: the effectiveness of budesonide therapy for Crohn's disease Systematic review: the effectiveness of budesonide therapy for Crohn's disease Kane S V, Schoenfeld P, Sandborn W J, Tremaine W, Hofer T, Feagan B G Authors' objectives To assess the effectiveness and safety of budesonide in comparison with corticosteroids, 5-aminosalicylic acid (5-ASA) or placebo, for inducing remission of active Crohn's (...) disease and for maintaining remission. Searching MEDLINE and EMBASE were searched from 1980 to 2001 for articles in any language. The search terms used were 'budesonide', 'Crohn disease', 'therapy', 'clinical trial' and 'randomized (pt)'. In addition, reference lists and conference proceedings of the American Gastroenterological Association and the American College of Gastroenterology were handsearched. Researchers and drug companies were contacted for unpublished trials. Study selection Study designs

2002 DARE.

77. Budesonide at different doses for chronic asthma. (Abstract)

Budesonide at different doses for chronic asthma. Inhaled budesonide (BUD) is available in a range of doses for treating chronic asthma.To quantitatively assess the efficacy and safety of budesonide at different doses in order to establish whether a clinically significant dose response profile exists.A search was carried out for Controlled and Randomised Clinical Trials (RCTs) using the Cochrane Airways Group trial register, correspondence with trial authors and the manufacturer.Randomised (...) trials in children and adults comparing one dose of budesonide to a second dose in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality.One reviewer extracted data; authors were contacted to clarify missing information. Quantitative analyses where undertaken using Review Manager.24 studies were selected for inclusion in the review (3907 subjects). In non-oral steroid treated, mild to moderately severe asthma no clinically worthwhile

2001 Cochrane

78. Budesonide for chronic asthma in children and adults. (Abstract)

Budesonide for chronic asthma in children and adults. Inhaled budesonide is a widely used inhaled corticosteroid for asthma.The objectives of this review was to compare the efficacy of budesonide with placebo in the treatment of chronic asthma.The Cochrane Airways Group Trial Register and reference lists of articles was searched. We contacted trialists for additional studies and searched abstracts of major respiratory society meetings (1997-1999).Randomised trials in children and adults (...) comparing budesonide to placebo in the treatment of chronic asthma.Two reviewers independently assessed articles for inclusion and methodological quality. One reviewer extracted data.43 studies met the inclusion criteria (2801 subjects). In non-oral steroid treated asthmatics, budesonide led to significant improvements in a number of measures of airway function. These included FEV1, Weighted Mean Difference (WMD) 3.7% predicted (95% CI 0.1, 7.2%); improvement in morning peak flow (PEF) from baseline WMD

2001 Cochrane

79. Budesonide for maintenance of remission in Crohn's disease. (Abstract)

Budesonide for maintenance of remission in Crohn's disease. The primary objective was to precisely derive an estimate of the efficacy of oral budesonide for the maintenance of remission in Crohn's disease.Medline 1966-September 2000 was searched using the text and key words "oral budesonide", "Crohn's disease", "Crohn disease", and "inflammatory bowel disease". Proceedings from the American Gastroenterology Association conference (1980-1998) were hand searched. Additionally, the Cochrane (...) Controlled Trials Register and the Inflammatory Bowel Disease Review Group Trials Registers were also searched. The manufacturer of oral budesonide was also contacted, as were some of the local trialists involved in the oral budesonide trials. Relevant articles were retrieved, and their reference lists were also reviewed.Randomized controlled trials of oral budesonide in which patients at entry were in remission with a Crohn's Disease Activity Index (CDAI) <= 150, and had disease restricted to the ileum

2001 Cochrane

80. Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice

Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice Andersson F, Kjellman M, Forsberg G, Moller C, Arheden L Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two maintenance therapies for the management of childhood asthma were compared: budesonide and sodium cromoglycate, both recommended strategies in Sweden. Type of intervention Treatment. Economic study type

2001 NHS Economic Evaluation Database.